Alnylam Pharmaceuticals (ALNY) Assets (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Assets came in at $5.6 billion in Q2 2026, up 21.74% YoY from $4.6 billion in Q2 2025, and up 8.37% on a QoQ basis from $5.1 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Assets (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Assets data on file, last reported at $5.6 billion in Q2 2026.
- Quarterly Assets rose 21.74% year-over-year to $5.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.6 billion (up 21.74% YoY) and the FY2025 annual result came in at $5.0 billion, up 17.13% from the prior year.
- Assets improved to $5.6 billion in Q2 2026, from $5.1 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $5.6 billion in Q2 2026 to a low of $3.3 billion in Q2 2022.
- A 5-year average of $4.1 billion and a median of $3.9 billion in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets dropped 5.1% — and 2026, when it climbed 21.74%.
- Tracing ALNY's Assets over 5 years: stood at $3.5 billion in 2022, then climbed by 7.99% to $3.8 billion in 2023, then grew by 10.71% to $4.2 billion in 2024, then gained by 17.13% to $5.0 billion in 2025, then gained by 11.93% to $5.6 billion in 2026.
- The last three Assets figures came in at $5.6 billion (Q2 2026), $5.1 billion (Q1 2026), and $5.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.56 Bn |
| Mar 31, 2026 | 5.13 Bn |
| Dec 31, 2025 | 4.97 Bn |
| Sep 30, 2025 | 4.85 Bn |
| Jun 30, 2025 | 4.57 Bn |
| Mar 31, 2025 | 4.21 Bn |
| Dec 31, 2024 | 4.24 Bn |
| Sep 30, 2024 | 4.21 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Mar 31, 2024 | 3.82 Bn |
| Dec 31, 2023 | 3.83 Bn |
| Sep 30, 2023 | 3.84 Bn |
| Jun 30, 2023 | 3.40 Bn |
| Mar 31, 2023 | 3.39 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.54 Bn |
| Jun 30, 2022 | 3.33 Bn |
| Mar 31, 2022 | 3.43 Bn |
| Dec 31, 2021 | 3.64 Bn |
| Sep 30, 2021 | 3.47 Bn |